Cole Schotz Advises RFI in Partnership to Create CBD Product Company Infusion Strategies

Jordan A. Fisch

June 12, 2019

Join Our Mailing List

Save as PDF

Cole Schotz P.C. represented RFI, LLC in connection with a strategic partnership with Elixinol Global Limited. The partnership was created via a newly incorporated entity, Infusion Strategies, which is owned by Elixinol Global’s wholly-owned subsidiary, Elixinol LLC, and RFI’s affiliate, RFITD Holdings, LLC.

Infusion Strategies will increase Elixinol’s exposure to the CBD-infused dietary supplement, nutraceutical, food and beverage industries via distribution to RFI’s customers. Elixinol will provide hemp expertise, supply chain stability, highest-quality Full-Spectrum and THC-free Hemp CBD extracts. RFI will manage the day to day operations of Infusion Strategies as well as provide global supply chain management, all non-CBD ingredients and the manufacturing expertise needed to custom blend formulations for tinctures, CBD-infused powders, capsules and other products.

Cole Schotz member Jordan A. Fisch advised RFI, LLC on the strategic partnership.

No aspect of this advertisement has been approved by the highest court in any state.

Results may vary depending on your particular facts and legal circumstances.

As the law continues to evolve on these matters, please note that this article is current as of date and time of publication and may not reflect subsequent developments. The content and interpretation of the issues addressed herein is subject to change. Cole Schotz P.C. disclaims any and all liability with respect to actions taken or not taken based on any or all of the contents of this publication to the fullest extent permitted by law. This is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Do not act or refrain from acting upon the information contained in this publication without obtaining legal, financial and tax advice. For further information, please do not hesitate to reach out to your firm contact or to any of the attorneys listed in this publication.